Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | F2RL1 | P55085 | 4/20 | 0.45 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 3/20 | 0.39 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.38 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18179253 | 0.90 | PDK1 (0.47) | PDK1PDK2PDK3PDK4F2RL1 | |
| SCHEMBL16614516 | 0.86 | F2RL1 (0.56) | PDK1PDK2PDK3PDK4F2RL1 | |
| SCHEMBL16614969 | 0.81 | F2RL1 (0.55) | PDK1PDK2PDK3PDK4F2RL1 | |
| SCHEMBL16614953 | 0.80 | F2RL1 (0.53) | PDK1PDK2PDK3PDK4F2RL1 | |
| SCHEMBL16614963 | 0.78 | F2RL1 (0.53) | PDK1PDK2PDK3PDK4F2RL1 | |
| SCHEMBL16614524 | 0.76 | F2RL1 (0.60) | PDK1PDK2PDK3PDK4F2RL1 | |
| SCHEMBL16614568 | 0.75 | F2RL1 (0.55) | PDK1PDK2F2RL1SMYD3GHSR | |
| SCHEMBL16614613 | 0.75 | F2RL1 (0.65) | F2RL1SMOGHSRMGLL | |
| SCHEMBL16614501 | 0.74 | F2RL1 (0.55) | F2RL1TRPC3TRPC7 | |
| SCHEMBL16598656 | 0.73 | F2RL1 (0.61) | PDK1PDK2F2RL1RBP4GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119282-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2019-04-25 | — | — | US | disclosed |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-10-27 | — | — | US | disclosed |
| WO-2015048245-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119282-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, F2R, F2RL3 | PDK1 526/4885PDK2 864/4885PDK3 1487/4885 |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, F2R, F2RL3 | PDK1 526/4885PDK2 864/4885PDK3 1487/4885 |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | F2RL1, F2R, F2RL3 | PDK1 526/4885PDK2 864/4885PDK3 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.